CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CRLHealthcarecriver.com
Latest available resultsSeptember 26, 2026Quarter · 10-Q filed Nov 4, 2026
Next reportFebruary 16, 2027after close · forecast 3.362 $/share
Revenue
$982.73M
▼ -2.2% vs prior year YoY
Net income
$333.07M
▲ +512.0% vs prior year YoY
EPS
6.86$
▲ +523.6% vs prior year YoY
Net margin
33.9%
▲ +28.5 pp vs prior year YoY
Revenue▼ -2.2%
Margins (% of revenue)Gross N/AOperatingNet
Net income▲ +512.0%
EPS▲ +523.6%
Financial statements
View 10-Q filed November 4, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $1.00B | $984.17M | $1.03B | $1.00B | $994.23M | $995.83M | $1.00B | $982.73M | ▼ -2.2% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Operating income | −$167.69M | $74.67M | $100.13M | $133.80M | −$283.44M | $119.90M | $119.89M | $202.64M | ▲ +51.4% |
| Net income | −$214.50M | $25.47M | $52.33M | $54.42M | −$276.56M | −$14.84M | −$1.48M | $333.07M | ▲ +512.0% |
| R&Dnever filed | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 0.50 $ | 1.06 $ | 1.10 $ | — | -0.30 $ | -0.03 $ | 6.86 $ | ▲ +523.6% |
| Margins (% of revenue) | |||||||||
| Gross | — | — | — | — | — | — | — | — | — |
| Operating | -16.7 % | 7.6 % | 9.7 % | 13.3 % | -28.5 % | 12.0 % | 11.9 % | 20.6 % | ▲ +7.3 pt |
| Net | -21.4 % | 2.6 % | 5.1 % | 5.4 % | -27.8 % | -1.5 % | -0.1 % | 33.9 % | ▲ +28.5 pt |
| Balance sheet | |||||||||
| Assets | $7.53B | $7.58B | $7.56B | $7.51B | $7.14B | $7.73B | $7.53B | $7.45B | ▼ -0.8% |
| Liabilities | $4.02B | $4.34B | $4.16B | $4.06B | $3.92B | $4.74B | $4.64B | $4.18B | ▲ +2.8% |
| Equity | $3.47B | $3.20B | $3.36B | $3.41B | $3.17B | $2.95B | $2.85B | $3.23B | ▼ -5.2% |
| Cash | $194.61M | $229.36M | $182.82M | $207.10M | $213.77M | $191.83M | $192.03M | $200.38M | ▼ -3.2% |
| Capital | |||||||||
| Shares outstanding | 51.14M | 49.12M | 49.21M | 49.22M | 49.23M | 48.17M | 47.74M | 47.92M | ▼ -2.6% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.